Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based drug developer Genesis Biopharma has entered into cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI).
Subscribe to our email newsletter
The agreement aims to develop adoptive cell immunotherapies that are intended to destroy metastatic melanoma cells using a patient’s tumor infiltrating lymphocytes.
Under the CRADA, the companies will develop approaches for large-scale production of tumor infiltrating lymphocytes that are in accord with good manufacturing practice (GMP) procedures suitable for use in treating patients with metastatic melanoma.
Additionally, CRADA will also provide assistance in in-vitro development of improved methods for the generation and selection of tumor infiltrating lymphocytes with anti-tumor reactivity from patients with metastatic melanoma.
Further, CRADA will allow the conduct of clinical trials using these improved methods of generating tumor infiltrating lymphocytes as well as improved adoptive cell therapy preparative regimens for the treatment of metastatic melanoma.